Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer
Urologic Clinics of North America
Angiogenesis; Antiangiogenic therapy; Prostate cancer; Treatment
Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach. © 2012 Elsevier Inc.
Lin, J., & Kelly, W. (2012). Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer. Urologic Clinics of North America, 39 (4). http://dx.doi.org/10.1016/j.ucl.2012.07.010